Video

Dr. Epstein-Peterson on Pivotal Clinical Trials in MCL

Author(s):

Zachary Epstein-Peterson, MD

In Partnership With:

Zachary Epstein-Peterson, MD, discusses pivotal clinical trials in the treatment of patients with mantle cell lymphoma.

Zachary Epstein-Peterson, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal clinical trials in the treatment of patients with mantle cell lymphoma (MCL).

Several clinical trials in MCL have shaped the way patients are treated, including the phase 3 SHINE trial (NCT01776840), Epstein-Peterson says. The trial evaluated the efficacy and safety of ibrutinib (Imbruvica) given in combination with bendamustine and rituximab (Rituxan) in patients who are 65 years of age or older with newly diagnosed MCL. Notably, the SHINE trial has informed new practices for transplant-ineligible patients, Epstein-Peterson adds.

In the transplant-eligible population, cytarabine is an important backbone of therapy, specifically for patients with newly diagnosed, TP53 wild-type disease, Epstein-Peterson continues. The importance of rituximab maintenance post stem cell transplant has also been emphasized with recent trials and has become an important conversation in the context of the COVID-19 pandemic, Epstein-Peterson concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Related Content
FDA accepts rivoceranib/camrelizumab NDA for HCC, acalabrutinib triplet yields 100% ORR in untreated mantle cell lymphoma, and more from OncLive this week.
October 26th 2024

The OncFive: Top Oncology Articles for the Week of 10/20

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Mark G. Kris, MD, thoracic medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center
October 14th 2024

Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
October 8th 2024

D-VRd Propels Toward SOC Status in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

Isabel Preeshagul, DO, MBS, of Memorial Sloan Kettering Cancer Center
October 7th 2024

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC